The Prevalence and Characteristics of Adrenal Incidentaloma

NCT04682938 | Completed DMC

• 1 other identifier: AI-China2020
• Study Type: observational
• Target: 25,356
• Locations: 1 country
• Sites: 1

Brief Summary

To investige the prevalence, characteristics and prognosis of adrenal incidentalomas in Chinese adults.

Conditions

Prevalence; Adrenal Incidentaloma

Keywords

Prevalence; characteristics; adrenal incidentaloma

Outcome Measures

Primary Outcomes (1)

• Prevalence and Characteristics of Adrenal Incidentaloma

  To investigate the prevalence and characteristics of Adrenal Incidentaloma in general population in China

  1 years

Secondary Outcomes (1)

• Steroid hormones in the function of Adrenal Incidentaloma

  1 years

Study Arms (1)

adrenal incidentalomas in Chinese community adults

On weekdays, the first 100 individuals, aged 18 to 78 years, taking health checkup in the Community Health Examination Center were invited to take part in the study.

Eligibility Criteria

• Age: 18 Years - 78 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Chinese community adults

You may qualify if:

• ·On weekdays, the first 100 individuals, aged 18 to 78 years, taking health checkup in the Community Health Examination Center were invited to take part in the study.

You may not qualify if:

• with known adrenal diseases;
• with continuous steroids or drug treatment that might influence cortisol secretion ordexamethasone metabolism and could not be stopped
• refuse to participate in the study.

Sponsors & Collaborators

• Chongqing Medical University: lead

Study Sites (1)

the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Chongqing, Chongqing Municipality, 400016, China

Location

Related Publications (4)

• Ichijo T, Ueshiba H, Nawata H, Yanase T. A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features. Endocr J. 2020 Feb 28;67(2):141-152. doi: 10.1507/endocrj.EJ18-0486. Epub 2019 Nov 7.

  PMID: 31694993 RESULT

• Lee JM, Kim MK, Ko SH, Koh JM, Kim BY, Kim SW, Kim SK, Kim HJ, Ryu OH, Park J, Lim JS, Kim SY, Shong YK, Yoo SJ; Korean Endocrine Society, Committee for Clinical Practice Guidelines. Clinical Guidelines for the Management of Adrenal Incidentaloma. Endocrinol Metab (Seoul). 2017 Jun;32(2):200-218. doi: 10.3803/EnM.2017.32.2.200.

  PMID: 28685511 RESULT

• Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016 Aug;175(2):G1-G34. doi: 10.1530/EJE-16-0467.

  PMID: 27390021 RESULT

• Jing Y, Hu J, Luo R, Mao Y, Luo Z, Zhang M, Yang J, Song Y, Feng Z, Wang Z, Cheng Q, Ma L, Yang Y, Zhong L, Du Z, Wang Y, Luo T, He W, Sun Y, Lv F, Li Q, Yang S. Prevalence and Characteristics of Adrenal Tumors in an Unselected Screening Population : A Cross-Sectional Study. Ann Intern Med. 2022 Oct;175(10):1383-1391. doi: 10.7326/M22-1619. Epub 2022 Sep 13.

  PMID: 36095315 DERIVED

Biospecimen

Retention: NONE RETAINED

Some subtye of disease should be diagnosed by DNA

MeSH Terms

Conditions

Adrenal incidentaloma

Study Officials

• Li Qifu, PhD

  First Affiliated Hospital of Chongqing Medical University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof.

Study Record Dates

• First Submitted: December 21, 2020
• First Posted: December 24, 2020
• Study Start: November 20, 2020
• Primary Completion: November 30, 2021
• Study Completion: November 30, 2021
• Last Updated: August 10, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)